VANDA PHARMACEUTICALS INC. Finite-Lived Intangible Assets, Accumulated Amortization
VANDA PHARMACEUTICALS INC. (VNDA) had Finite-Lived Intangible Assets, Accumulated Amortization of $34.78 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent › Intangible Asset, Finite-Lived, after Accumulated Amortization
us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization · last filed 2026-08-06
- 2026-06-30: Finite-Lived Intangible Assets, Accumulated Amortization $34.78M.
- 2026-03-31: Finite-Lived Intangible Assets, Accumulated Amortization $32.79M.
- 2025-12-31: Finite-Lived Intangible Assets, Accumulated Amortization $30.80M.
- 2025-09-30: Finite-Lived Intangible Assets, Accumulated Amortization $29.05M.
| Period end | Finite-Lived Intangible Assets, Accumulated Amortization |
|---|---|
| 2026-06-30 | $34.78M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $32.79M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $30.80M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $29.05M 10-Q · filed 2025-10-30 |
| 2025-06-30 | $27.30M 10-Q · filed 2025-07-31 |
| 2025-03-31 | $25.55M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $23.80M 10-K · filed 2026-02-12 |
| 2024-09-30 | $22.05M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $20.30M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $18.54M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $16.52M 10-K · filed 2025-02-14 |
| 2022-12-31 | $14.44M 10-K · filed 2024-02-08 |
| 2018-12-31 | $36.40M 10-K · filed 2019-02-19 |
| 2018-09-30 | $36.02M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $35.62M 10-Q · filed 2018-08-02 |
| 2018-03-31 | $35.22M 10-Q · filed 2018-05-02 |
| 2017-12-31 | $34.87M 10-K · filed 2019-02-19 |
| 2017-09-30 | $34.44M 10-Q · filed 2017-11-08 |
| 2017-06-30 | $34.01M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $33.58M 10-Q · filed 2017-05-03 |
| 2016-12-31 | $33.12M 10-K · filed 2018-02-15 |
| 2016-09-30 | $31.02M 10-Q · filed 2016-11-03 |
| 2016-06-30 | $28.07M 10-Q · filed 2016-07-28 |
| 2016-03-31 | $25.13M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $22.19M 10-K · filed 2017-02-17 |
| 2015-09-30 | $19.25M 10-Q · filed 2015-11-04 |
| 2015-06-30 | $16.30M 10-Q · filed 2015-07-31 |
| 2015-03-31 | $13.36M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $9.22M 10-K · filed 2016-02-12 |
| 2013-12-31 | $6.96M 10-K · filed 2014-02-25 |
| 2013-09-30 | $6.59M 10-Q · filed 2013-11-08 |
| 2013-06-30 | $6.21M 10-Q · filed 2013-07-31 |
| 2013-03-31 | $5.84M 10-Q · filed 2013-05-10 |
| 2012-12-31 | $5.47M 10-K · filed 2014-02-25 |
| 2011-12-31 | $3.97M 10-K · filed 2013-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |